Who are Insmed's investors?

Insmed's investors include Bessemer Venture Partners, F-Prime Capital, Foresite Capital, Hercules Capital, Inc., OrbiMed, Prospect Venture Partners, Ridgeback Capital, NVIDIA.

Insmed

NASDAQ: INSM

Incorporated in Virginia · 1,767 employees on LinkedIn · 8 known investors

Find your way into Insmed

Paths you didn't know you had: your email and LinkedIn already hold routes to the Insmed team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Will Lewis Chair and Chief Executive OfficerWill Lewis has held roles in government, investment banking, and biopharmaceuticals, and has served as Chair and Chief Executive Officer of Insmed since 2012, leading its growth into a company of over 1,700 employees focused on serious lung diseases.

Geoffrey AllanCEOformer

Sara BonsteinChief Financial Officer

Roger AdsettChief Operating Officer

Martina Flammer Chief Medical OfficerMartina Flammer is a physician-executive with over 20 years in biopharmaceutical leadership, holding an MD from the University of Vienna Medical School and an MBA from NYU Stern. She previously held roles including Chief Medical Officer at Boehringer Ingelheim and VP of Clinical Development and Medical Affairs there, as well as leadership positions at Pfizer, and now serves as Chief Medical Officer at Insmed.

S. Nicole Schaeffer Chief People Strategy OfficerS. Nicole Schaeffer is Chief People Strategy Officer at Insmed, with over 25 years of experience in human resources, organizational development, and corporate operations across life science companies.

Michael A. SmithChief Legal Officer

Investors · 8

Bessemer Venture Partnerslisted by Bessemer Venture PartnersSan Francisco · $50K – $100M

How we know: Bessemer Venture Partners's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Hercules Capital, Inc.listed by Hercules Capital, Inc.San Mateo

How we know: Hercules Capital, Inc.'s portfolio page · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Prospect Venture Partnerslisted by Prospect Venture PartnersMenlo Park · $3M – $5M

How we know: Prospect Venture Partners's portfolio page · Not right? Tell us

Ridgeback Capitallisted by Ridgeback CapitalNew York

How we know: Ridgeback Capital's portfolio page · Not right? Tell us

NVIDIAreportedSanta Clara

How we know: funding news · Not right? Tell us

Founder mafia

2 people who came through Insmed went on to found or lead other companies.

Philip YoungCBO and EVPFounded AmpliPhi Biosciences Al AltomariBoard of DirectorsFounded Agile Therapeutics

Related companies · 1

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

Companies working in the same space as Insmed.

Acquisitions · 2

Early investors' stakes continue via these deals

Adrestia Therapeutics

Early-stage drug discovery platform, acquired by Insmed

Transave

Transave was a biopharmaceutical company developing inhaled liposomal antibiotic therapies for serious lung infections, including its lead candidate Arikace for cystic fibrosis-related pseudomonas infections.

Frequently asked questions

What does Insmed do?: Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
Who are Insmed's investors?: Insmed's investors include Bessemer Venture Partners, F-Prime Capital, Foresite Capital, Hercules Capital, Inc., OrbiMed, Prospect Venture Partners, Ridgeback Capital, NVIDIA.